JPWO2023078113A5 - - Google Patents

Info

Publication number
JPWO2023078113A5
JPWO2023078113A5 JP2024525790A JP2024525790A JPWO2023078113A5 JP WO2023078113 A5 JPWO2023078113 A5 JP WO2023078113A5 JP 2024525790 A JP2024525790 A JP 2024525790A JP 2024525790 A JP2024525790 A JP 2024525790A JP WO2023078113 A5 JPWO2023078113 A5 JP WO2023078113A5
Authority
JP
Japan
Prior art keywords
cdr
sequence
seq
cdrs
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525790A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541048A (ja
JP2024541048A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/127036 external-priority patent/WO2023078113A1/en
Publication of JP2024541048A publication Critical patent/JP2024541048A/ja
Publication of JP2024541048A5 publication Critical patent/JP2024541048A5/ja
Publication of JPWO2023078113A5 publication Critical patent/JPWO2023078113A5/ja
Pending legal-status Critical Current

Links

JP2024525790A 2021-11-02 2022-10-24 抗cd122抗体、抗cd132抗体、及び関連する二重特異性結合性タンパク質 Pending JP2024541048A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/128208 2021-11-02
CN2021128208 2021-11-02
PCT/CN2022/127036 WO2023078113A1 (en) 2021-11-02 2022-10-24 Anti-cd122 antibodies, anti-cd132 antibodies, and related bispecific binding proteins

Publications (3)

Publication Number Publication Date
JP2024541048A JP2024541048A (ja) 2024-11-06
JP2024541048A5 JP2024541048A5 (https=) 2025-10-30
JPWO2023078113A5 true JPWO2023078113A5 (https=) 2025-10-30

Family

ID=86240641

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525790A Pending JP2024541048A (ja) 2021-11-02 2022-10-24 抗cd122抗体、抗cd132抗体、及び関連する二重特異性結合性タンパク質

Country Status (7)

Country Link
US (1) US20250002594A1 (https=)
EP (1) EP4426742A4 (https=)
JP (1) JP2024541048A (https=)
CN (1) CN118251416A (https=)
CA (1) CA3236138A1 (https=)
TW (1) TW202334219A (https=)
WO (1) WO2023078113A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN116789828B (zh) * 2023-05-31 2023-11-17 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种抗cd132的单克隆抗体及其应用
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
CN117886940B (zh) * 2024-01-19 2024-11-19 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 人源化抗人cd132单克隆抗体及其应用
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2026033139A1 (en) 2024-08-09 2026-02-12 Twain Therapeutics Pte. Ltd. Antigen-binding molecules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011127324A2 (en) * 2010-04-08 2011-10-13 JN Biosciences, LLC Antibodies to cd122
BR112016015140A2 (pt) * 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
PT3328894T (pt) * 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
CN111954680B (zh) * 2017-11-10 2024-03-15 新加坡科技研究局 IL2Rβ/共同γ链抗体
TW202031683A (zh) * 2018-11-09 2020-09-01 新加坡商優其洛伊生物私人有限公司 介白素2受體β(IL2Rβ)/共同γ鏈抗體
MX2021008958A (es) * 2019-02-01 2021-11-04 Regeneron Pharma Proteínas de unión a antígeno del receptor gamma anti-il2.

Similar Documents

Publication Publication Date Title
JP7773975B2 (ja) 抗pd-l1単一ドメイン抗体ならびにその誘導体および使用
JP7562528B2 (ja) 抗体及びその用途
CN113015749B (zh) 靶向cd3的抗体、双特异性抗体及其用途
CN114502591B (zh) 靶向bcma的抗体、双特异性抗体及其用途
JP7840955B2 (ja) 抗ヒトb7-h3抗体及びその利用
CN113416258A (zh) 一种多特异性抗体及其制备方法和用途
JP7766672B2 (ja) TGF-β RII突然変異体及びその融合タンパク質
TW202334219A (zh) 抗cd122抗體、抗cd132抗體及相關的雙特異性結合蛋白
TW202132351A (zh) 抗cd47/抗pd-l1抗體及其應用
CN114667296B (zh) 一种双特异性抗体及其用途
CN113754771A (zh) 一种抗pdl1×egfr的双特异性抗体
JPWO2023078113A5 (https=)
JP7812988B2 (ja) Lewis Yに対するヒト化抗体
JPWO2022042488A5 (https=)
CN114072428B (zh) 一种靶向PD-L1和TGF-β的融合蛋白及其用途
CN119816523A (zh) 抗Nectin-4抗体和包含其的多特异性抗体
CN111138539B (zh) 一种靶向Frizzled7人源化抗体及其制备方法与应用
IL312060A (en) Bispecific CD16A binders
EP4717714A1 (en) Anti-pd-1-anti-vegf bispecific antibody, pharmaceutical composition thereof and use thereof
CN113754776A (zh) 一种抗pd-l1/vegf融合蛋白
CN121263447A (zh) Trop2抗体
JP2025535104A (ja) B7h3/pdl1二重特異性抗体およびその医薬組成物ならびにその使用
CN115073596B (zh) 一种人源化Claudin18.2抗体及其应用
CN113527491B (zh) 人源化抗体、嵌合抗原受体、核酸、载体、细胞及应用
JP2024509369A (ja) 抗pd-l1抗体及びその使用